These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 21699487)

  • 21. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
    Kapur S; Zipursky R; Jones C; Remington G; Houle S
    Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database.
    Kim S; Zavitsanou K; Gurguis G; Webster MJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):683-94. PubMed ID: 22356822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
    Farde L; Wiesel FA; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1988 Jan; 45(1):71-6. PubMed ID: 2892477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
    Inoue A; Nakata Y
    Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Microglial hypothesis of schizophrenia].
    Kanba S; Kato T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Feb; 34(1):11-3. PubMed ID: 25069267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation.
    Zhang F; Liu J; Shi JS
    Eur J Pharmacol; 2010 Jun; 636(1-3):1-7. PubMed ID: 20361959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory treatment in schizophrenia.
    Müller N; Myint AM; Krause D; Weidinger E; Schwarz MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():146-53. PubMed ID: 23178230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain.
    Sakuma K; Komatsu H; Maruyama M; Imaichi S; Habata Y; Mori M
    PLoS One; 2015; 10(2):e0118510. PubMed ID: 25693194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [
    Holmes SE; Hinz R; Drake RJ; Gregory CJ; Conen S; Matthews JC; Anton-Rodriguez JM; Gerhard A; Talbot PS
    Mol Psychiatry; 2016 Dec; 21(12):1672-1679. PubMed ID: 27698434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.
    Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.